Ex-Turning Point execs plan to have their next bet, Avenzo, on the Nasdaq next summer
The crew at Turning Point Therapeutics is back together for a new biotech that wants to acquire early-stage oncology small molecules, including antibody drug conjugates, and potentially form partnerships with China-based drug developers for ex-China rights as it eyes a speedy leap onto the Nasdaq around this time next year, CEO Athena Countouriotis told Endpoints … Continue reading Ex-Turning Point execs plan to have their next bet, Avenzo, on the Nasdaq next summer
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed